Injecting without getting infected: Injectors' strategies to prevent HIV and HCV;Pincharse sin infectarse: Estrategias para prevenir la infección por el VIH y el VHC entre usuarios de drogas inyectables

Trastornos Adictivos

Volumn 9, Issue 4, 2007, Pages 260-268

  Mateu Gelabert, P ^a   Friedman, S ^a   Sandoval, M ^a  

^a NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

Author keywords

Hepatitis C; HIV; IDU; Infection; Prevention

Indexed keywords

ARTICLE; CONTROLLED STUDY; DRUG USE; HEALTH PROGRAM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; PREVALENCE;

EID: 37849036053     PISSN: 15750973     EISSN: 15782638     Source Type: Journal    
DOI: 10.1016/S1575-0973(07)75655-6     Document Type: Article

References (30)

1. Centers for Disease Control and Prevention, Health Resources and Services Administration, National Institute on Drug Abuse, Administration, The Substance Abuse and Mental Health Administration. HIV prevention bulletin: Medical advice for persons who inject illicit drugs. Washington, D.C: U.S. Department of Health and Human Services; 1997.
2. Chiasson RE, Baccheti P, Osmond D, Brodie B, Sande MA, Moss AR. Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA. 1989;261:561-5.
3. Friedman SR, Jose B, Deren S, Des Jarlais DC, Neaigus A, National AIDS Research Consortium. Risk factors for HIV seroconversion among out-of-treatment drug injectors in high- and low-seroprevalence cities. Am J Epidemiol. 1995;142:864-74.
4. Grund JPC, Friedman SR, Stern JS, Jose B, Neaigus A, Curtis R, et al. Syringe-mediated drug sharing among injecting drug users: Patterns, social context and implications for transmission of blood-borne pathogens. Soc Sci Med. 1996;42:691-703.
5. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001;91:42-6.
6. Jose B, Friedman SR, Neaigus A, Curtis R, Des Jarlais DC. «Frontloading» is associated with HIV infection among drug injectors in New York City. Eighth International Conference on AIDS; 1992.
7. Jose B, Friedman SR, Curtis R, Grund JPC, Goldstein MF, Ward TP, et al. Syringe-mediated drug-sharing (backloading): A new risk factor for HIV among injecting drug users. AIDS. 1993;7:1653-60.
8. Koester SK. Water, cookers, and cottons: Additional risks for intravenous drug abusers. Rockville, MD: National Institute on Drug Abuse; 1989.
9. Marmor M, Des Jarlais DC, Cohen H, Friedman SR, Beatrice ST, Dubin N, et al. Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City. AIDS. 1987;1:39-44.
10. Metzger DS, Woody GE, McLellan AT, O'Brien CP, Druley P, Navaline H, et al. Human immunodeficiency virus seroconversion among intravenous drug users in-and out-of-treatment: An 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993;6:1049-56.
11. Metzger DS, Navaline H, Woody GE. Drug abuse treatment as AIDS prevention. Public Health Rep. 1998;113:97-106.
12. Patrick DM, Strathdee SA, Archibald CP, Ofner M, Craib KJ, Cornelisse PG, et al. Determinants of HIV seroconversion in injection drug users during a period of rising prevalence in Vancouver. Int J STD AIDS. 1997;8:437-45.
13. Schoenbaum EE, Hartel D, Selwyn PA, Klein RS, Davenny K, Rogers M, et al. Risk factors for human immunodeficiency virus infection for intravenous drug users. N Engl J Med. 1989;321:874-9.
14. Singer M, Dai H, Weeks M, Malave D. AIDS risk perception among women drug users in Hartford, CT. En: Stevens S, Tortu S, Coyle S, editors. Women, drug use, and HIV infection. New York: Haworth Medical Press; 1989.
15. Stimson G. The health and social costs of drug injecting: The challenge to developing countries. 6th International Conference on the Reduction of Drug Related Harm; 1995.
16. Stimson G, Des Jarlais DC, Ball A. Drug injecting and HIV infection: Global dimensions and local responses. London: UCL Press; 1998.
17. Tortu S, Beardsley M, Deren S. AIDS risk among female partners of injection drug users: Implications for prevention. NIDA Res Monogr. 1993;132:283.
18. Vlahov D, Muñoz A, Anthony JC, Cohn S, Celentano DD, Nelson KE. Associations of drug injection patterns with antibody to HIV type 1 among intravenous drug users in Baltimore, Maryland. Am J Epidemiol. 1990;132:847-56.
19. Vlahov D, Khabbaz RF, Cohn S, Galai N, Taylor E, Kaplan JF. Incidence and risk factors for human T-lymphotropic virus type II seroconversion among injecting drug users in Baltimore, Maryland. J Acquir Immune Defic Syndr. 1995;9:89-96.
20. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, et al. Hepatitis C virus seroconversion among young injection drug users: Relationships and risks. Am J Infect Dis. 2002;186:1558-64.
21. Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155:645-53.
22. Des Jarlais D, Perlis T, Kamyar A, Torian LV, Beatrice S, Milliken J, et al. HIV Incidence Among Injection Drug Users in New York City, 1990 to 2002: Use of Serologic Test Algorithm to Assess Expansion of HIV Prevention Services. Am J Public Health. 2005;95:1439-44.
23. Díaz T, Des Jarlais DC, Vlahov D, Perlis T, Edwards V, Friedman SR, et al. Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health. 2001;91:23-30.
24. Mateu-Gelabert P, Treloar C, Agullo V, Milagros S, Valderrama JC, Maher L, et al. How can hepatitis C be prevented in the long term? Int J Drug Policy. 2007;18:338-40.
25. Sternin J, Choo R. The power of positive deviancy. An effort to reduce malnutrition in Vietnam offers an important lesson about managing change. Harv Bus Rev. 2000;78(1):14-5.
26. Wray JD. Can we learn from successful mothers? J Trop Pediatr Environ Child Health. 1972;18:279.
27. Mateu-Gelabert P, Maslow C, Flom PL, Sandoval M, Bolyard M, Friedman SR. Keeping it together: stigma, response, and perception of risk in relationships between drug injectors and crack smokers, and other community residents. AIDS Care. 2005;17:802-13.
28. Friedman SR, Maslow C, Bolyard M, Sandoval M, Mateu-Gelabert P, Neaigus A. Urging others to be healthy: «Intravention» by injection drug users as a community prevention goal. AIDS Education and Prevention. 2004;16:250-63.
29. Friedman SR, Bolyard M, Maslow C, Mateu-Gelabert P, Sandoval M. Harnessing the power of social networks to reduce HIV risk. Focus. 2005;20:5-6.
30. Mateu-Gelabert P, Bolyard, M, Maslow C, Sandoval M, Flom P, Friedman SR. For the Common Good: Measuring residents' efforts to protect their community from drug and sex related harm. SAHARA's Journal of Social Aspects of HIV/AIDS (2007 submitted).